Multivariate analysis of clinical, morphologic, cytogenetic, and molecular variables
| . | All patients (n = 1332) . | Patients no older than 60 (n = 720) . | ||||||
|---|---|---|---|---|---|---|---|---|
| CR rate . | EFS . | OS . | ||||||
| P . | OR (95% CI) . | P . | OR (95% CI) . | P . | OR (95% CI) . | P . | OR (95% CI) . | |
| Age ≤/> 37 | ||||||||
| Age (≤ 60 vs > 60) | < .001 | 0.27 (0.21–0.34) | < .001 | 1.80 (1.57–2.07) | < .001 | 1.97 (1.66–2.18) | < .001 | 1.68 (1.32–2.15) |
| Cytogenetic risk group | ||||||||
| Intermediate vs favorable | < .001 | 2.84 (1.62–4.97) | < .001 | 0.43 (0.31–0.60) | < .001 | 0.51 (0.36–0.70) | <.001 | 0.49 (0.33–0.73) |
| Intermediate vs unfavorable | < .001 | 0.46 (0.34–0.62) | < .001 | 1.66 (1.40–1.97) | < .001 | 1.71 (1.46–2.01) | < .001 | 1.55 (1.21–1.97) |
| NPM1-mut/FLT3-ITDneg | — | — | .003 | 0.73 (0.60–0.90) | NS | — | NS | — |
| NPM1-mut/FLT3-ITDpos | — | — | NS | — | NS | — | NS | — |
| NPM1-wt/FLT3-ITDpos | — | — | NS | — | NS | — | NS | — |
| History of AML (de novo vs secondary) | < .001 | 0.57 (0.42–0.76) | NS | — | NS | — | NS | — |
| Dysplasia (MLD vs dys 0+1) | NS | — | NS | — | NS | — | NS | — |
| . | All patients (n = 1332) . | Patients no older than 60 (n = 720) . | ||||||
|---|---|---|---|---|---|---|---|---|
| CR rate . | EFS . | OS . | ||||||
| P . | OR (95% CI) . | P . | OR (95% CI) . | P . | OR (95% CI) . | P . | OR (95% CI) . | |
| Age ≤/> 37 | ||||||||
| Age (≤ 60 vs > 60) | < .001 | 0.27 (0.21–0.34) | < .001 | 1.80 (1.57–2.07) | < .001 | 1.97 (1.66–2.18) | < .001 | 1.68 (1.32–2.15) |
| Cytogenetic risk group | ||||||||
| Intermediate vs favorable | < .001 | 2.84 (1.62–4.97) | < .001 | 0.43 (0.31–0.60) | < .001 | 0.51 (0.36–0.70) | <.001 | 0.49 (0.33–0.73) |
| Intermediate vs unfavorable | < .001 | 0.46 (0.34–0.62) | < .001 | 1.66 (1.40–1.97) | < .001 | 1.71 (1.46–2.01) | < .001 | 1.55 (1.21–1.97) |
| NPM1-mut/FLT3-ITDneg | — | — | .003 | 0.73 (0.60–0.90) | NS | — | NS | — |
| NPM1-mut/FLT3-ITDpos | — | — | NS | — | NS | — | NS | — |
| NPM1-wt/FLT3-ITDpos | — | — | NS | — | NS | — | NS | — |
| History of AML (de novo vs secondary) | < .001 | 0.57 (0.42–0.76) | NS | — | NS | — | NS | — |
| Dysplasia (MLD vs dys 0+1) | NS | — | NS | — | NS | — | NS | — |
NPM1-wt/FLT3-ITDneg was set as the reference group.
dys 0+1 indicates dysplasia in 0 or 1 lineage; MLD, dysplasia in 2 or 3 lineages according to WHO classification19 ; NPM1-FLT3 group; mut, mutant; wt, wild type; NS, not significant; and —, no data.